Diligence memo · auto-generated · as of July 3, 2026
RenaBio Therapeutics, Inc.
RenaBio Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
RenaBio Therapeutics, Inc. operates in Pharma, based in NATICK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
RenaBio Therapeutics, Inc. has raised $1.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.0M on 2024-03-28.
Most recent recorded round closed around 2025-02-20.
Valuation (modeled)modeled
Provath models RenaBio Therapeutics, Inc. at approximately $852K (range $189K–$1.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.22× the median modeled value of Seed Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 16 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 4.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 38% of Pharma peers (310 compared).
Modeled value ranks above 20% of those peers.
Closest niche peers: Antigenix Therapeutics, Inc., Strategikon Pharma, Inc., Fitness Fingerprint Therapeutics, Inc., NeuroEM Therapeutics, Inc., iQure Pharma Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.